SCHEMBL29436231

SCHEMBL29436231

O=C(Cn1nc(-c2ccc(OC(F)F)nc2)ccc1=O)NCc1ccccc1Cl

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 5/20 0.59
▸ MAPT P10636 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ PTGES O14684 2/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ TSHR P16473 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23495213 1.00 TP53 (0.59) TP53MAPTSMN1; SMN2POLBALDH1A1
SCHEMBL23495246 0.88 TP53 (0.59) TP53MAPTSMN1; SMN2POLBALDH1A1
SCHEMBL23495166 0.88 TP53 (0.62) TP53MAPTSMN1; SMN2POLBALDH1A1
SCHEMBL23495138 0.88 TP53 (0.59) TP53MAPTSMN1; SMN2POLBALDH1A1
SCHEMBL29436205 0.88 TP53 (0.59) TP53MAPTSMN1; SMN2POLBALDH1A1
SCHEMBL29436197 0.85 MAPT (0.65) TP53MAPTSMN1; SMN2ALDH1A1PTGES
SCHEMBL23495354 0.85 MAPT (0.65) TP53MAPTSMN1; SMN2ALDH1A1PTGES
SCHEMBL29436263 0.84 TP53 (0.59) TP53MAPTSMN1; SMN2ALDH1A1PTGES
SCHEMBL23495429 0.84 TP53 (0.59) TP53MAPTSMN1; SMN2ALDH1A1PTGES
SCHEMBL23495270 0.83 POLB (0.49) TP53MAPTSMN1; SMN2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340526-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2025-11-06 — — US disclosed
US-12415794-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-09-16 — — US disclosed
EP-4248972-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 — — EP disclosed
US-20230293518-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-09-21 — — US disclosed
EP-3877052-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2023-08-16 — — EP disclosed
US-20220081410-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2022-03-17 — — US disclosed
US-11236065-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPECUTICS, INC. (US) 2022-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293518-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 TP53 4843/4885MAPT 1863/4885SMN1; SMN2 3/4885
US-20220081410-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A TP53 4800/4885MAPT 1810/4885SMN1; SMN2 9/4885
US-12415794-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A TP53 4800/4885MAPT 1810/4885SMN1; SMN2 9/4885
US-11236065-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A TP53 4800/4885MAPT 1810/4885SMN1; SMN2 9/4885
US-20250340526-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A TP53 4800/4885MAPT 1810/4885SMN1; SMN2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback